Longevity Clinic Berlin: What You Need to Know Before Booking

Your search query was probably something like “longevity clinic experiences Berlin”. Maybe also “longevity clinic costs” or “longevity clinic Germany”. You have heard about these modern prevention centers, read headlines about whole-body MRIs and cancer detection from blood, and seen the price ranges: from a few hundred euros to more than €15,000.

What can you really expect? How do you separate serious medical diagnostics from expensive wellness? What should you look out for before booking an appointment?

This article is not advertising copy. It is a guide to help you make the right decision, based on medical criteria rather than marketing promises.

What is a longevity clinic — and what is it not?

The term “longevity” is used excessively. Let’s start with a clear definition.

A longevity clinic is a physician-led medical facility that specializes in comprehensive, proactive preventive medicine. Its goal: systematically measuring and optimizing your health to maximize your healthy years of life, your healthspan. Early disease detection is one part of that, though it is not the full picture.

This distinguishes it from three other concepts:

Your general practitioner often works within a symptom-driven healthcare system and provides defined preventive services such as the statutory health check-up. A longevity clinic analyzes your health status more broadly before symptoms occur, with the aim of identifying risks early (Bundesministerium für Gesundheit, 2026; Gemeinsamer Bundesausschuss, 2021).

A wellness spa focuses on well-being and relaxation. A longevity clinic works with hard medical data and a long-term strategy supervised by physicians.

A single check-up such as the German statutory “Check-up 35” is a clearly limited preventive examination. A longevity clinic offers a level of diagnostic detail that goes far beyond this and integrates the results into a full overall picture (Bundesministerium für Gesundheit, 2026; Gemeinsamer Bundesausschuss, 2021).

The promise: a more comprehensive, precise, and strategic view of your health than is usually possible in the standard healthcare system. How do you make sure this promise is actually kept?

The guide: 7 criteria for your longevity clinic experience

Before booking an appointment, you should assess every potential clinic using these seven criteria.

1. Medical leadership and expertise

The most important question comes first: Who holds medical responsibility? Is the clinic led by experienced specialists with a scientific background, or by entrepreneurs with a strong marketing department?

Check specifically:

Specialist qualification: Is there a team of internists, cardiologists, radiologists, and other specialists behind the program?

Scientific background: Has the medical leadership conducted research in relevant areas? Are there publications in recognized medical journals?

Clinical experience: Do the physicians come from reputable hospitals or university clinics?

A medical director who has conducted research at institutions such as Stanford and published more than 100 scientific articles signals that the clinic has a scientific foundation. Media presence alone is not a quality marker.

1. Diagnostic scope and evidence

A “comprehensive blood panel” can mean everything or nothing. Serious providers are transparent about what they measure and why.

Basic diagnostics beyond the standard

A good starting point is a set of biomarkers that are often missing from a normal check-up but are critical for risk assessment:

ApoB (apolipoprotein B): A more precise marker of cardiovascular risk than conventional LDL cholesterol, especially when LDL-C and particle number diverge, such as in insulin resistance, elevated triglycerides, or metabolic syndrome (Sniderman et al., 2019; Mach et al., 2020).

Lp(a) (lipoprotein(a)): A genetically determined, independent, and likely causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. It is usually not meaningfully changed through diet or exercise (Kronenberg et al., 2022).

hs-CRP (high-sensitivity C-reactive protein): Measures low-grade inflammatory activity, which is associated with cardiovascular risk. The JUPITER trial showed that patients with elevated hs-CRP and low LDL had 44% fewer major cardiovascular events under rosuvastatin therapy (Ridker et al., 2008).

HOMA index: An estimate of insulin resistance based on fasting glucose and fasting insulin. It can provide indications of early metabolic dysfunction, even when fasting glucose or HbA1c are still normal; longitudinal data show that changes in insulin sensitivity and glucose metabolism can become visible years before a type 2 diabetes diagnosis (Matthews et al., 1985; Tabák et al., 2009).

Advanced functional and imaging diagnostics

Blood values are only one part of the picture. A good longevity clinic integrates several data sources:

Lung function: For a complete analysis including lung volumes, residual volume, and airway resistance, body plethysmography is an appropriate method. For alveolar gas exchange, diffusing capacity, usually DLCO, is additionally required. Together, these procedures provide parameters that simpler methods cannot capture (Bhakta et al., 2023; Stanojevic et al., 2022).

Performance diagnostics: Cardiorespiratory fitness, ideally measured as VO₂max or VO₂peak via cardiopulmonary exercise testing, is considered one of the strongest single predictors of all-cause mortality. A study with more than 122,000 patients from the Cleveland Clinic (Mandsager et al., JAMA Network Open 2018) showed that poor cardiorespiratory fitness was associated with a higher mortality risk than classic risk factors such as smoking or hypertension.

Imaging: Extended ultrasound of the heart, abdomen, and thyroid belongs to the basic setup.

High-end diagnostics for more detailed insights

The most advanced programs offer technologies from current medical research:

Whole-body MRI: A radiation-free method used to examine the body for structural abnormalities and possible tumor signals. Meta-analyses in oncology contexts report high diagnostic accuracy, for example a pooled sensitivity of around 90% and specificity of around 95% for whole-body DWI-MRI in primary and metastatic malignancies. For screening asymptomatic populations, however, long-term clinical benefit has not yet been conclusively proven, and incidental findings can be common (Li et al., 2014; Kwee & Kwee, 2019; Petralia et al., 2021). More on whole-body MRI diagnostics at YEARS.

Liquid biopsy: A blood test that, depending on the method, searches for circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or other tumor signals. Multi-cancer early detection tests can screen for dozens of cancer types at the same time, often with the aim of detecting signals before symptoms begin. The technology is promising, but it is not a replacement for established screening procedures and it is not a diagnosis. Sensitivity and specificity vary strongly depending on the test, tumor type, and stage; in early stages, especially stage I, sensitivity is substantially lower for many MCED approaches than in advanced tumors. Clinical utility is still being evaluated in prospective studies (Klein et al., 2021; Schrag et al., 2023; Wade et al., 2025).

1. Scientific context and the limits of screening

This is where the seriousness of a clinic becomes most visible. A good physician does not sell miracle promises, but explains opportunities and risks. This is the prevention dilemma.

Every screening examination carries the risk of:

False-positive findings: The test raises an alarm even though everything is fine. The consequence can be unnecessary anxiety and further examinations.

Overdiagnosis: A real but harmless abnormality is found, although it would never have become a problem. In slow-growing prostate cancer at an advanced age, treatment can sometimes do more harm than good.

Incidental findings: A whole-body MRI shows a small kidney cyst. In many cases harmless, yet the uncertainty remains.

A responsible clinic explains these aspects to you in the initial consultation. It makes clear that a screening test is not a diagnosis, but a risk assessment that may require further work-up depending on the finding. Technologies such as the liquid biopsy at YEARS are potentially useful tools that require careful medical interpretation.

1. The costs: What does a longevity clinic cost in Germany?

Prices vary significantly depending on scope and provider. As a rough guide, offers can be divided into four categories:

Modular individual check-ups (€250 – €1,500): Individual physicians or smaller practices offer extended check-ups, often as a collection of lab values with basic examinations. The weak point is often the lack of integration of results into an overall picture.

Ambulatory one-day programs (€1,800 – €3,500): Providers such as YEARS in Berlin bundle a comprehensive diagnostic set with dozens of biomarkers, functional diagnostics, and imaging into a single day. For many people, this is a sensible entry point because it provides a robust baseline.

Advanced ambulatory programs (€7,000 – €10,000): Include whole-body MRI, liquid biopsy, epigenetic age testing, and biobanking for future analyses.

Inpatient premium programs and genetics (€15,000 – €50,000+): Multi-day stays or programs with whole-genome sequencing, analyzing hereditary diseases, cancer risks, and pharmacogenetics.

Four factors drive costs:

Technology: An MRI scanner costs several million euros to purchase.

Staff: A team of specialists, radiologists, and scientists affects pricing differently than a single-physician practice.

Time: The hours a physician spends analyzing a 60-page report and then discussing it with you are a major cost driver.

Research: Clinics with their own clinical registry or ongoing studies reinvest part of their revenue into data evaluation.

Ask specifically: What do I get for my money? A list of tests or an integrated strategy? You can find an overview of the YEARS programs here.

1. Your strategy consultation: Data without a plan is worthless

You have completed 6 hours of testing. Your blood was analyzed for 120 markers. The MRI produced 2,000 images. What happens with all of that now?

The most valuable part of your longevity clinic experience is what follows the measurements: the strategy consultation with the physician.

A good provider does not simply hand you a folder full of lab values. It brings all results together into a coherent overall picture, prioritizes your individual risks, and gives you a concrete, actionable 12-month plan. It tells you clearly which three things you should change now, and which twenty findings may be interesting but are not urgent.

This consultation should take place after all relevant findings are available. Lab, radiology, genetics, everything together. Only then does data collection become real preventive medicine.

1. Data protection and your medical data

You generate a large amount of highly sensitive data. Ask specifically:

Data storage: Are your data stored on GDPR-compliant servers in the EU?

Biobanking: If biobanking is offered, you need separate, explicit consent. You need to know who is allowed to use your samples for what type of research, and you must be able to withdraw this right.

Anonymization: For research purposes, your data should be pseudonymized or anonymized.

A transparent clinic proactively provides you with privacy policies and consent documents without you having to ask for them.

1. Private insurance reimbursement and GOÄ billing

Most longevity programs are self-pay services. For people with statutory health insurance, reimbursement through the regular statutory insurance benefit catalog is usually not intended.

For privately insured patients, the situation can be better, but there is no guarantee. The key lies in the billing format. Does the clinic bill according to the GOÄ, the German medical fee schedule? This is the official basis for private medical services in Germany and a prerequisite for any reimbursement request.

The chance of partial reimbursement can increase if diagnostics produce medically relevant findings: undetected insulin resistance, hypertension, or elevated Lp(a). Thorough diagnostics can provide starting points that make a medical justification for further measures possible. Whether and to what extent private insurance reimburses costs depends on the individual tariff, the medical justification, and the specific invoice.

Speak with your insurer in advance and ask the clinic for concrete experience values. You can often find further answers in the FAQs of serious providers.

Longevity clinic experiences in Berlin: A concrete example

Let’s apply this checklist to YEARS in Berlin.

1. Medical leadership: Dr. Jan K. Hennigs, specialist in internal medicine and pulmonology with a research background at Stanford University and more than 120 publications (YEARS, 2026b; Premium Medical Circle, n.d.). (✓)
2. Diagnostic scope:

Core® program (€1,900): 87+ biomarkers including ApoB, hs-CRP, Lp(a), HOMA index, body plethysmography, 12-lead ECG, extended ultrasound, VO₂max, 3D body scan, AI skin screening (YEARS, 2026a). (✓)

Evolve® program (€7,600): Everything from Core, plus whole-body MRI, liquid biopsy (TruCheck), 120+ biomarkers including hormones such as testosterone, and biobanking (YEARS, 2026a; YEARS, 2026c). (✓)

1. Scientific context: YEARS communicates the limits of screening procedures openly and positions itself as an evidence-based clinic. The “Clinic-as-a-Study” model indicates a scientific standard that goes beyond a purely service-based offering. (✓)
2. Costs: Three clearly named programs at €1,900, €7,600, and €16,900, without hidden add-on services in the fine print (YEARS, 2026a). (✓)
3. Strategy consultation: A health report and a dedicated medical consultation after the diagnostics day are part of the programs (YEARS, 2026a). (✓)
4. Data protection: Explicit consent processes for the biobank in the Evolve® and Ultimate® programs. (✓)
5. Private insurance reimbursement: Billing according to GOÄ. (✓)

This example shows how you can use the criteria. YEARS is not the only option on the market. But you now have a benchmark for assessing any offer.

The most important experience is your own

Anyone searching for “longevity clinic experiences” has already taken a decisive step: thinking proactively about their own health before something goes wrong.

Do not let yourself be guided by lifestyle promises or fear-based marketing. Ask about medical expertise. Press for diagnostic detail. Demand transparency on costs and scientific context.

A longevity clinic provides data, medical interpretation, and a strategic plan. The implementation remains with you.

Sources

Bhakta, N. R., McGowan, A., Ramsey, K. A., Borg, B. M., Bradley, J. M., Coates, A. L., Culver, B. H., Graham, B. L., Hall, G. L., Holland, A. E., Kaminsky, D. A., McCormack, M. C., Rosenfeld, M., Stanojevic, S., & Thompson, B. R. (2023). European Respiratory Society/American Thoracic Society technical standard on standardisation of the measurement of lung volumes: 2023 update. European Respiratory Journal.

Bundesministerium für Gesundheit. (2026). Gesundheits-Check-up.

Gemeinsamer Bundesausschuss. (2021). Gesundheitsuntersuchungs-Richtlinie.

Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., Jamshidi, A., Kurtzman, K. N., Seiden, M. V., Swanton, C., Liu, M. C., & et al. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167–1177.

Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., McNeal, C. J., Moriarty, P. M., Natarajan, P., Nordestgaard, B. G., Parhofer, K. G., Virani, S. S., von Eckardstein, A., Watts, G. F., Stock, J. K., Ray, K. K., & Catapano, A. L. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925–3946.

Kwee, R. M., & Kwee, T. C. (2019). Whole-body MRI for preventive health screening: A systematic review of the literature. Journal of Magnetic Resonance Imaging, 50(5), 1489–1503.

Li, B., Li, Q., Nie, W., & Liu, S. (2014). Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: A meta-analysis. European Journal of Radiology, 83(2), 338–344.

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., Tokgozoglu, L., & Wiklund, O. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188.

Mandsager, K., Harb, S., Cremer, P., Phelan, D., Nissen, S. E., & Jaber, W. (2018). Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open, 1(6), e183605.

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419.

Petralia, G., Padhani, A. R., Pricolo, P., Zugni, F., Martinetti, M., Summers, P. E., Grazioli, L., Colagrande, S., Giovagnoni, A., Bellomi, M., & Koh, D. M. (2021). Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: Review and recommendations. Cancer Imaging, 21, 43.

Premium Medical Circle. (n.d.). Dr. Jan K. Hennigs.

Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., ... & JUPITER Study Group. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195–2207.

Schrag, D., Beer, T. M., McDonnell, C. H., Nadauld, L. D., Dilaveri, C. A., Reid, R., Klein, E. A., & et al. (2023). Blood-based tests for multicancer early detection (PATHFINDER): A prospective cohort study. The Lancet, 402(10409), 1251–1260.

Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287–1295.

Stanojevic, S., Kaminsky, D. A., Miller, M. R., Thompson, B., Aliverti, A., Barjaktarevic, I., Cooper, B. G., Culver, B., Derom, E., Hall, G. L., Hallstrand, T. S., Leuppi, J. D., MacIntyre, N., McCormack, M., Rosenfeld, M., Swenson, E. R., & Graham, B. L. (2022). ERS/ATS technical standard on interpretive strategies for routine lung function tests. European Respiratory Journal, 60(1), 2101499.

Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. The Lancet, 373(9682), 2215–2221.

Wade, R., Corbett, M., Griffin, S., McKenna, C., Soares, M., Sculpher, M., Eastwood, A., & Palmer, S. (2025). Multi-cancer early detection tests for general population screening: A systematic literature review. Health Technology Assessment, 29(1), 1–108.

YEARS. (2026a). Longevity Check-up in Berlin — messen, was wirklich zählt.

YEARS. (2026b). Dr. med. Jan K. Hennigs.

YEARS. (2026c). Evolve – MRI + 120 Biomarkers.